The invention relates to an oral drug composite of beta-cyclodextrin edaravone inclusion, comprising the compositions in parts by weight: 1 part of edaravone and 6-100 parts of cyclodextrin. Based on the optimization scheme, the mass ratio of the edaravone and the cyclodextrin is 1:6-50, wherein the mass ratio of beta-cyclodextrin to the cyclodextrin is 1:6-20, and the mass ratio of mixed cyclodextrin containing the beta-cyclodextrin is 1:8-50. A preparation method comprises the following steps of mixing the beta-cyclodextrin or the mixed cyclodextrin containing the beta-cyclodextrin with 1-5times mass of water, adding the edaravone with the selected mass ratio or adding a solution prepared from the edaravone and 10 times soluble organic solvent, grinding or stirring, vaporizing and eliminating water at the temperature no higher than 60 DEG C, and decompression drying to obtain a white powdery inclusion complex. A contrast test is carried out on the invention and edaravone injection on sale, the absolute bioavailability of an inclusion complex preparation thereof can reach above 55 percent; and compared with a common edaravone suspension preparation (attached drawing 6), the relative bioavailability of the invention reaches up to about 1000 percent.